Trial Profile
Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.